The Billion-Dollar Biotech
June 3, 2015
Moderna Therapeutics has big ambitions and a bankroll to match. How a fledgling start-up became one of the most highly valued private drug firms ever.
Continue reading at Nature.
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.